Mar 29, 2023 / 01:30PM GMT
Paul Andrew Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst
Great. Thank you, and thanks, everyone, for continuing along to listen-in. It's my pleasure to be sitting here with Vasant Jadhav an SVP level rep of Alnylam in the research group. Just for everyone listening and this should be obvious, but I think we're largely going to focused on your efforts in CNS this morning. But Vasant, maybe you can just kind of give folks a little bit of background about yourself. And with that, maybe just a brief overview of Alnylam's efforts in CNS and more various programs stands.
Vasant Jadhav -
Yes, absolutely. Well, first of all, thank you Paul for this opportunity. My name, Vasant Jadhav. I've been leading our RNAi platform efforts at Alnylam from last 9 years or so. And prior to that, I was at Sirna, Merck in the same field of RNAi therapeutics. It's been about 20 years or so working in this field, pretty much right from the beginning. And at Alnylam, my efforts are focused on the technology of the
Alnylam Pharmaceuticals Inc at Stifel CNS Days (Virtual) Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers